Innoviva (INVA) Q4 2025 earnings summary

Executive summary

• Achieved 15% year-over-year revenue growth to $411.3 million and net income exceeding $270 million for full year 2025.

• IST segment delivered 47% year-over-year U.S. net product sales growth, reaching $119.2 million.

• Expanded commercial portfolio with the U.S. launch of ZEVTERA and FDA approval of NUZOLVENCE for uncomplicated urogenital gonorrhea.

• Initiated a $125 million share repurchase program in Q4 2025.

Financial highlights

• Q4 2025 total revenue was $114.6 million, up 25% from Q4 2024; full year revenue was $411.3 million, up 15% year-over-year.

• Q4 2025 net product sales more than doubled to $59.1 million; full year net product sales rose 77% to $172.1 million.

• Q4 2025 net income was $164.2 million ($2.19 basic EPS); full year net income was $271.2 million ($4.02 basic EPS).

• Q4 2025 income from operations was $39.0 million; full year income from operations was $163.7 million.

• Cash and cash equivalents totaled $550.9 million at year-end 2025.

Outlook and guidance

• Anticipates $150 million or more in IST U.S. net product sales in 2026.

• Plans to commercialize NUZOLVENCE in the U.S. in the second half of 2026, either independently or with a partner.